Good morning, you're tuned into Markets Desk.
Eli Lilly is printing money in the GLP-one space. The pharmaceutical giant reported nearly thirteen billion dollars in quarterly revenue from its tirzepatide franchise alone, and management is guiding higher from here. Demand for Mounjaro and Zepbound continues to outpace supply constraints, cementing Lilly's dominance in the weight-loss and diabetes treatment market.
Shifting to semiconductors, Goldman Sachs is sounding a cautionary note on retail behavior in chip stocks. Traders at the firm say investors have moved beyond buying the dip and are now chasing momentum in what Goldman is calling a mania trade. The concern is concentration risk — crowded positions that could unwind sharply if sentiment turns, leaving late entrants badly exposed.
And on the artificial intelligence infrastructure theme, the real cash flow story isn't in the headline applications. It's in the industrial backbone powering the build-out — power management, cooling, and grid connectivity companies that hyperscalers simply cannot function without. As capital expenditure from Big Tech accelerates, those unglamorous suppliers are quietly delivering outsized returns.
That's the tape. Markets Desk, signing off the floor.
